Radiology · Renal Angiomyolipoma

Variants & Look-Alikes: Not All AMLs are the Same

At a Glance

Classic renal angiomyolipomas usually contain visible fat and are benign, but fat-poor tumors can resemble kidney cancer on scans. Epithelioid AML is a rare subtype that can behave aggressively, so tissue diagnosis and closer follow-up may be needed.

When you first hear the diagnosis of a renal angiomyolipoma (AML), it is usually described as a benign, fat-containing growth. However, not all AMLs follow this “classic” pattern. While most are composed of a mix of fat, muscle, and blood vessels, some look and behave differently. Understanding these variations is critical because it determines whether your medical team can simply watch the tumor or if they need to intervene ^[1]^[2].

Fat-Poor AML: An Imaging Challenge

The “classic” AML is easy for radiologists to identify because it contains visible pockets of macroscopic fat, which appear very dark on a CT scan ^[3]. However, about 5% of AMLs are described on imaging as fat-poor, meaning they contain very little fat, or fat-invisible, meaning the fat cannot be seen on standard imaging at all ^[1].

Because fat-poor AMLs appear as solid masses on a scan, they can look almost identical to Renal Cell Carcinoma (RCC), the most common type of kidney cancer ^[4].

The Diagnostic Challenge: On a CT scan, both fat-poor AML and RCC can “enhance” (brighten) when contrast dye is used ^[5].
When Imaging Isn’t Enough: Because imaging cannot definitively prove that a fat-poor mass is a benign AML, your doctor may recommend a renal mass biopsy (using a needle to take a small tissue sample) or surgery to resolve the uncertainty and confirm the diagnosis ^[1]^[2].

Epithelioid AML: A Microscopic Diagnosis

While “fat-poor” describes how a tumor looks on a scan, epithelioid AML (eAML) describes what the tumor cells look like under a microscope. This is a rare form where the tumor is made up largely of a specific type of cell called an epithelioid cell ^[6]^[7].

Unlike the classic triphasic AML, which is usually entirely benign, the epithelioid variant has malignant potential ^[8]. This means it has the ability to behave aggressively, recur after surgery, or in rare cases, spread to other organs ^[8]^[9].

Identifying High-Risk Features in Epithelioid AML

Because the behavior of epithelioid AML varies, pathologists look for specific “adverse features” on the biopsy or surgical sample. A specialist pathologist will evaluate these factors together to estimate your risk:

Necrosis: Areas of cell death within the tumor, suggesting rapid growth ^[10].
Mitotic Activity: A high “mitotic count,” meaning the cells are dividing quickly ^[8].
Markedly Abnormal Nuclei: Cells that look heavily distorted or atypical under the microscope ^[11].
Size and Invasion: Tumors larger than 7 cm or those that have grown into the surrounding blood vessels ^[11]^[8].

No single feature guarantees the tumor will act aggressively, but if your pathology report mentions a combination of these features, your care plan will likely involve a multidisciplinary team and long-term follow-up to ensure any changes are caught early ^[8]^[12].

Variant / Term	What It Means	Behavior
Classic AML	Has visible fat on a scan	Usually benign when confirmed; very low risk ^[1]
Fat-Poor AML	Lacks visible fat on a scan	An imaging term; could be a benign AML, but could be kidney cancer until proven otherwise ^[4]
Epithelioid AML	A pathology diagnosis made under a microscope	Potentially aggressive; requires specialist follow-up ^[8]

Common questions in this guide

Why can a fat-poor AML be mistaken for kidney cancer?

A fat-poor or fat-invisible angiomyolipoma contains little or no fat that can be seen on standard imaging. It may therefore appear as a solid mass that brightens after contrast, much like renal cell carcinoma. Imaging alone may not prove which diagnosis is present, so a biopsy or surgery may be recommended.

What does an epithelioid AML diagnosis mean?

Epithelioid AML is a rare subtype in which many of the tumor cells have an epithelioid appearance under the microscope. Unlike classic AML, it can behave aggressively, recur after surgery, or rarely spread to other organs. This is why specialist pathology review and follow-up are important.

Which findings make epithelioid AML more concerning?

Pathologists consider necrosis, a high number of dividing cells, markedly abnormal-looking nuclei, a tumor larger than 7 cm, and growth into nearby blood vessels. These findings are assessed together rather than in isolation. No single feature guarantees that the tumor will behave aggressively.

Can a kidney mass biopsy tell the difference between fat-poor AML and renal cell carcinoma?

A renal mass biopsy can provide tissue that may help distinguish a fat-poor AML from renal cell carcinoma. Because imaging and biopsy may not always resolve the uncertainty, some people are advised to have surgery instead. The recommendation depends on the imaging and the information needed to confirm the diagnosis.

How is follow-up different for epithelioid AML?

Classic AML is usually benign when the diagnosis is confirmed and generally has very low risk. Epithelioid AML can have malignant potential, so follow-up may be more intensive and longer term, especially when the tumor has concerning pathology, is large, or involves blood vessels. Your care team can set the schedule based on your complete report.

Does a family history of tuberous sclerosis matter when evaluating AML?

A family history of Tuberous Sclerosis Complex may be relevant when an epithelioid variant is being considered. It does not by itself establish the subtype or predict how the tumor will behave. Your medical team can explain whether it changes the evaluation or monitoring plan.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on angiomyolipoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.What percentage of epithelioid cells were found in my pathology report?
2.Does my tumor show any 'adverse features' like necrosis or high mitotic activity?
3.If my imaging is 'fat-poor,' how certain are you that this is not renal cell carcinoma?
4.Would a renal mass biopsy provide enough information to distinguish between these subtypes, or is surgery recommended?
5.If I have the epithelioid variant, how does our monitoring schedule change compared to a classic AML?

References (12)

1
Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.
Park BK
AJR. American journal of roentgenology 2017; (209(4)):826-835 doi:10.2214/AJR.17.17973.
PMID: 28726505
2
A young female case of primary renal carcinoid tumor mimicking fat-poor angiomyolipoma.
Kato R, Fukushima H, Kobayashi M, et al.
International cancer conference journal 2018; (7(4)):156-158 doi:10.1007/s13691-018-0341-2.
PMID: 31149537
3
Renal Angiomyolipoma Based on New Classification: How to Differentiate It From Renal Cell Carcinoma.
Park BK
AJR. American journal of roentgenology 2019; (212(3)):582-588 doi:10.2214/AJR.18.20408.
PMID: 30620673
4
Renal angiomyolipomas: Typical and atypical features on computed tomography and magnetic resonance imaging.
Labra A, Schiappacasse G, Constenla D, Cristi J
World journal of radiology 2025; (17(2)):104282 doi:10.4329/wjr.v17.i2.104282.
PMID: 40060953
5
Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation.
Tanaka H, Fujii Y, Tanaka H, et al.
International journal of urology : official journal of the Japanese Urological Association 2017; (24(7)):511-517 doi:10.1111/iju.13354.
PMID: 28600877
6
[Epithelioid angiomyolipoma of the kidney: About one case and malignant features evaluation].
Lavrut PM, Paparel P, Decaussin-Petrucci M
Annales de pathologie 2017; (37(2)):182-187 doi:10.1016/j.annpat.2017.01.005.
PMID: 28318774
7
Renal epithelioid angiomyolipoma: computed tomography manifestation and radiologic-pathologic correlation depending on different epithelioid component percentages.
Luo C, Liu Z, Gao M, et al.
Abdominal radiology (New York) 2022; (47(1)):310-319 doi:10.1007/s00261-021-03313-3.
PMID: 34664098
8
Epithelioid renal angiomyolipoma: Clinical characteristics, treatment strategies, and oncological outcomes-An individual patient data meta-analysis of 259 cases.
Haselhoff FJ, Kaufmann E, Mattei A, et al.
Urologic oncology 2026; (44(10)):759-766 doi:10.1016/j.urolonc.2026.08.006.
PMID: 42660691
9
Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.
Pecoraro A, Amparore D, Bertolo R, et al.
Urologic oncology 2025; doi:10.1016/j.urolonc.2025.10.018.
PMID: 41330802
10
♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study.
Anwaier A, Xu WH, Tian X, et al.
BMC urology 2022; (22(1)):148 doi:10.1186/s12894-022-01101-9.
PMID: 36096809
11
Beyond the epithelioid percentage: Adverse-feature burden for prognostic stratification of renal epithelioid angiomyolipoma - A cohort study and individual patient data meta-analysis.
Wang C, Liu S, Liu F, et al.
Annals of diagnostic pathology 2026; (86()):152725 doi:10.1016/j.anndiagpath.2026.152725.
PMID: 42826451
12
Renal Epithelioid Angiomyolipoma: Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic Features.
Sangoi AR, Lobo A, Jha S, et al.
The American journal of surgical pathology 2025; (49(8)):781-788 doi:10.1097/PAS.0000000000002411.
PMID: 40289813

This page explains renal angiomyolipoma variants for educational purposes and does not replace medical advice. Your radiologist, pathologist, and urologist can interpret your imaging and pathology and recommend appropriate follow-up.

Guide Contents